(b)
pharmaceutical form, route of administration (may be excluded for oral solid dose forms), quantity of dosage units and, in the case of clinical trials which do not involve the blinding of the label, the name/identifier and strength/potency;
← anx_VI__cpt_1__cpt_2__cpt_1__point_4__point_a__text_1 · All articles · anx_VI__cpt_1__cpt_2__cpt_1__point_4__point_b__text_1 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.